Navigation Links
Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
Date:4/10/2013

SEATTLE, April 10, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled receptor (GPCR) unlocked by Omeros, significantly improved function from experimental autoimmune encephalomyelitis (EAE) in mice. Using its proprietary high-throughput Cellular Redistribution Assay (CRA), Omeros believes that it alone has identified compounds that functionally interact with GPR17 and has patents pending that are broadly directed to any such compounds active at the receptor.

Having discovered compounds that functionally interact with GPR17, Omeros previously showed that GPR17 antagonists promote generation of mature oligodendrocytes, the cells that produce myelin. Myelin is a key component of the proper functioning of the central nervous system, and myelin deficiency is a hallmark of a large number of neurodegenerative autoimmune diseases, including MS. In this EAE model, animals treated with GPR17-targeting compounds, compared to untreated animals, significantly improved mean clinical scores, which quantify disease progression by measuring motor dysfunction and are used as a surrogate indicator of demyelination.

"Our GPCR platform – built around our proprietary CRA – continues to unlock wholly new drug targets, and we expect that our sole knowledge of the identities of their interacting compounds together with our patent positions will give Omeros exclusive control of those receptors," stated Gregory A. Demopulos , M.D., chairman and chief executive officer of Omeros. "GPR17 is one of those
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
2. Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
3. Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
4. Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
5. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
6. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
7. Omeros Announces Toxicology Study Data from MASP-2 Inhibitor
8. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
9. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
10. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
11. Omeros is Not Aware of Any Justification for Share Price Movement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 30, 2015  Astellas today announced ... evaluating the efficacy and safety of intravenous (IV) ... sulfate), under development for adults with candidemia and ... the study demonstrated that the trial did not ... treatment response in isavuconazole-treated patients at the end ...
(Date:7/29/2015)... , July 29, 2015  Unilife Corporation ("Unilife" or ... a developer, manufacturer and supplier of injectable drug delivery ... strategy that provides the Company with flexibility and control ... Unilife has signed an equity purchase agreement for up ... ("LPC"), a Chicago -based institutional investor, ...
(Date:7/29/2015)... 29, 2015  According to data released today by ... average monthly Medicare Part D premium is expected to ... was originally projected, the Pharmaceutical Care Management Association (PCMA) ... to be a bright spot in American health care. ... region and using cutting edge, cost-saving tools like pharmacy ...
Breaking Medicine Technology:Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5
... avoid damage to heart ... ... plaque,and blood clot that break loose during percutaneous coronary intervention,(PCI) has failed ... with acute coronary syndromes, a condition that,encompasses unstable angina and a type ...
... bests clopidogrel, CHICAGO, March 29 Prasugrel ... with acute coronary syndromes (ACS) more,effectively than clopidogrel, ... risk of,thrombosis, or blood clotting, inside the coronary ... Trial to Assess Improvement in Therapeutic,Outcomes by Optimizing ...
Cached Medicine Technology:Filter Fails to Improve PCI Outcomes in Acute Coronary Syndromes 2Filter Fails to Improve PCI Outcomes in Acute Coronary Syndromes 3TRITON-TIMI 38 Stent Analysis Favors Prasugrel 2TRITON-TIMI 38 Stent Analysis Favors Prasugrel 3
(Date:7/30/2015)... ... July 30, 2015 , ... Eyepartner is ... victims in San Diego, California’s Gaslamp Quarter Plaza for five years this September. ... actively monitor the area for any suspicious activity. These cameras are in place ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Telemedicine Association (ATA) ... Tradeshow focused exclusively on telemedicine, telehealth and mHealth. The meeting, expected to attract ... take place May 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting attracts ...
(Date:7/30/2015)... San Diego, CA (PRWEB) , ... July 30, ... ... company has been consistently growing into one of the largest, family-owned low cost ... offered across residential and commercial applications, as well as growing their company to ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... health care throughout Orange, Riverside, Los Angeles, and San Bernardino counties, today announced ... the new Palliative Care Administrator. Dr. Demoratz is a strong proponent of early ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... “Beachside Nursing Center,” to announce its position as one of Medicare’s top-rated ... and staff members support the CMS rating system, which monitors health inspections, ...
Breaking Medicine News(10 mins):Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 2Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:Beachside Nursing Center Releases New Video 2
... the Prime Minister, Premiers and Chief Ministers urging the ... and childcare workers are trained in recognizing and handling ... COAG also should ensure the provision of legal immunity ... severe allergic reactions. ,'Greater awareness and ...
... says that Tai Chi, may be helpful in preventing ... been found not only to increase// the immunity to ... to varicella vaccine as well. ,This National ... clinical trial to suggest that a behavioral intervention, alone ...
... in Mumbai will soon start an integrated trauma care facility ... to patients on way to a hospital from an accident ... Physicians of Indian Origin (AAPI), the emergency medical service and ... within minutes of an accident. ,"The ambulance would ...
... Radiologists using computer-aided detection software for mammograms are more ... than "human reviewers using// their eyes and experience," and ... to a study. ,CAD systems use complex ... a radiologist to review. The systems, which cost $50,000 ...
... - supporting research and providing education, advocacy and ... - today said physicians should consider lowering the ... with multiple myeloma. ,High dose dexamethasone ... treatment of myeloma alone and in combination with ...
... McGill University in Montreal in Canada have found that by ... alter the speed with which the mice// learned to perform ... develop drugs to improve memory. ,The finding paves ... loss and dementia, but similar drugs might also improve the ...
Cached Medicine News:Health News:COAG Must Make Combating Severe Allergies A National Priority 2Health News:Tai Chi may Be Useful to Prevent Shingles in Older Adults 2Health News:Mumbai to Have Integrated Trauma Care Facility 2Health News:Mumbai to Have Integrated Trauma Care Facility 3Health News:New Clinical Trial Results Could Improve Survival for Myeloma Patients 2Health News:New Clinical Trial Results Could Improve Survival for Myeloma Patients 3Health News:Canadian Researchers Raise Hopes of Treatment for Memory Loss 2
...
... System* was designed to provide ... range of prosthesis for a ... With the addition of the ... a more complete range of ...
...
... The only shoulder prosthesis with ... experience in thousands of patients. Ideal ... resulting in 3 or 4 part ... greater than 50%, head-splitting fractures, disabling ...
Medicine Products: